secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034585
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Therapeutics 2024 revenue $138.1M (up 36% YoY); CX-2051 data expected 1H 2025; headcount cut 40%
--------------------------------------------------------------------------------

- Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.
- Lead program CX-2051 (EpCAM ADC) Phase 1a initial data in advanced CRC expected 1H 2025; dose escalation at 7th dose level.
- CX-801 (IFN-alpha) Phase 1a translational data in melanoma expected 2H 2025; monotherapy dose exceeds approved peginterferon dose.
- CX-904 (EGFR-CD3 TCE) development discontinued by mutual decision with Amgen.
- January 2025 restructuring reduced headcount ~40% to extend cash runway into Q2 2026; Astellas milestone triggered $5M payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/0000950170-25-034585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/ctmx-20250306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer